全文获取类型
收费全文 | 1350075篇 |
免费 | 97077篇 |
国内免费 | 2688篇 |
专业分类
耳鼻咽喉 | 19075篇 |
儿科学 | 44379篇 |
妇产科学 | 39551篇 |
基础医学 | 196894篇 |
口腔科学 | 37126篇 |
临床医学 | 114263篇 |
内科学 | 267149篇 |
皮肤病学 | 28022篇 |
神经病学 | 106075篇 |
特种医学 | 52864篇 |
外国民族医学 | 386篇 |
外科学 | 207808篇 |
综合类 | 28056篇 |
现状与发展 | 1篇 |
一般理论 | 342篇 |
预防医学 | 96990篇 |
眼科学 | 30273篇 |
药学 | 103619篇 |
4篇 | |
中国医学 | 2967篇 |
肿瘤学 | 73996篇 |
出版年
2018年 | 13459篇 |
2016年 | 11422篇 |
2015年 | 13219篇 |
2014年 | 18102篇 |
2013年 | 27388篇 |
2012年 | 37556篇 |
2011年 | 40136篇 |
2010年 | 23988篇 |
2009年 | 22421篇 |
2008年 | 38553篇 |
2007年 | 41707篇 |
2006年 | 42074篇 |
2005年 | 41233篇 |
2004年 | 40095篇 |
2003年 | 38922篇 |
2002年 | 38527篇 |
2001年 | 60568篇 |
2000年 | 61934篇 |
1999年 | 52554篇 |
1998年 | 15070篇 |
1997年 | 13498篇 |
1996年 | 13689篇 |
1995年 | 12889篇 |
1994年 | 12278篇 |
1993年 | 11336篇 |
1992年 | 42085篇 |
1991年 | 41448篇 |
1990年 | 40812篇 |
1989年 | 39625篇 |
1988年 | 36906篇 |
1987年 | 36084篇 |
1986年 | 34457篇 |
1985年 | 32799篇 |
1984年 | 24425篇 |
1983年 | 21261篇 |
1982年 | 12687篇 |
1981年 | 11204篇 |
1979年 | 23030篇 |
1978年 | 16140篇 |
1977年 | 13988篇 |
1976年 | 13189篇 |
1975年 | 14495篇 |
1974年 | 17041篇 |
1973年 | 16416篇 |
1972年 | 15628篇 |
1971年 | 14515篇 |
1970年 | 13474篇 |
1969年 | 12980篇 |
1968年 | 12219篇 |
1967年 | 10705篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
34.
35.
36.
M. Iachina P.M. Ljungdalh R.G. Sørensen L. Kaerlev J. Blaakær O. Trosko N. Qvist B.M. Nørgård 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):115-123
Aims
To examine the influence of pre-existing psychiatric disorder on the choice of treatment in patients with gynaecological cancer.Materials and methods
The analyses were based on all patients who underwent surgical treatment for endometrial, ovarian or cervical cancer who were registered in the Danish Gynecological Cancer Database in the years 2007–2014 (3059 patients with ovarian cancer, 5100 patients with endometrial cancer and 1150 with cervical cancer). Logistic regression model and Cox regression model, adjusted for relevant confounders, were used to estimate the effect of pre-existing psychiatric disorder on the course of cancer treatment. Our outcomes were (i) presurgical oncological treatment, (ii) macroradical surgery for patients with ovarian cancer, (iii) radiation/chemotherapy within 30 days and 100 days after surgery and (iv) time from surgery to first oncological treatment.Results
In the group of patients with ovarian cancer, more patients with a psychiatric disorder received macroradical surgery versus patients without a psychiatric disorder, corresponding to an adjusted odds ratio of 1.24 (95% confidence interval 0.62–2.41) and the chance for having oncological treatment within 100 days was odds ratio = 1.26 (95% confidence interval 0.77–2.10). As for patients with endometrial cancer, all outcome estimates were close to unity. The adjusted odds ratio for oncological treatment within 30 days after surgery in patients with cervical cancer with a history of psychiatric disorder was 0.20 (95% confidence interval 0.03–1.54).Conclusions
We did not find any significant differences in the treatment of ovarian and endometrial cancer in patients with pre-existing psychiatric diagnoses. When it comes to oncological treatment, we suggest that increased attention should be paid to patients with cervical cancer having a pre-existing psychiatric diagnosis. 相似文献37.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献38.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献39.
40.